Aksel Siva, EAN 2019 - Treatment strategies in multiple sclerosis

Aksel Siva (Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey), a valued member of our European editorial board, talks to us about the topic of the interactive session he participated in focusing on treatment strategies in progressive multiple sclerosis.
Questions
1. What criteria should guide a clinician’s decision as to when to initiate and/or escalate disease-modifying treatment in progressive multiple sclerosis (MS)? (0:04)
2. What is the current status of research into predictors in progressive MS? (1:40)
Speaker disclosure: Aksel Siva has received honoraria for educational presentations and consultation fees from Novartis, Sanofi-Genzyme, F. Hoffmann-La Roche, Biogen Idec/Gen Pharma of Turkey, Merck Serono and Teva; received travel and registration coverage for attending several national or international congresses or symposia from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Genzyme and , F. Hoffmann-La Roche.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.